ATHNreport Summer 2008
HTCs across the country are seeing tangible financial benefits of the ATHN Affiliate program. With the newly announced data management funding program and travel support to the ATHN Data Summit, more and more HTCs recognize that the ATHN Affiliate program is an initiative whose time is now. To date, 67 HTCs have become ATHN Affiliates—more than double the number of those signed just a few brief months ago. The real strength of this growing membership is not merely in the numbers, it’s in the breadth and depth of the experience, expertise and data collection the Affiliates bring in support of ATHN’s mission, vision and values.
Recognizing that data quality counts highly and that quality data takes trained resources, ATHN has launched ATHNdata.quality.counts, our funding program to support data management activities in eligible federally funded HTCs. Drawing on ATHN’s unrestricted grant from Novo Nordisk, Inc., the ATHN Board authorized a $400,000 initial round of funding for HTC data management. (See related article for details.)
As momentum for the ATHN Affiliate program grows, we become even more excited about our upcoming, inaugural Data Summit scheduled for July 31 through August 1st in downtown Chicago. ATHN Data Summit 2008 will be an opportunity for ATHN Affiliates from across the country to bond, as well as to provide input on how ATHN can help you and your patients. The comprehensive Summit agenda includes an update on key ATHN activities and milestones, education sessions on Lab Tracker and emergency preparedness as well as working groups on rare bleeding disorders and thrombosis, to help set our future direction. We look forward to seeing you there!
It’s been a year of good news on other fronts as well. Halfway into our second year of operations, ATHN continues to meet or exceed the goals we set to fulfill our mission and vision. The generous and ongoing support of Novo Nordisk, Inc., is allowing us to further develop the infrastructure that is needed to support mission-driven projects with a robust, secure, national database of comprehensive, standardized data about the care and treatment of people with bleeding and thrombotic disorders. Development of this database is enabling ATHN to move forward on our research agenda and secure funding for targeted projects, such as our work on rare coagulation factor deficiencies.
These milestones affirm ATHN’s key role in the hemostasis and thrombotic community and our growing ability to help advance and improve the care of individuals affected by bleeding and thrombotic disorders.
